---
annotation-target: bloodbld2022017278c.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-23T12:58:30.503Z","updated":"2022-09-23T12:58:30.503Z","document":{"title":"bloodBLD2022017278C.pdf","link":[{"href":"urn:x-pdf:a9844b104ac7e761f01900b1d6ff1440"},{"href":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf"}],"documentFingerprint":"a9844b104ac7e761f01900b1d6ff1440"},"uri":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","selector":[{"type":"TextPositionSelector","start":233,"end":469},{"type":"TextQuoteSelector","exact":"mprehensive, longitudinalanalysis of molecular measurable residual disease (MRD) assessments inpatients with mantle cell lymphoma (MCL) treated with chemoimmunotherapy,autologous stem cell transplant (ASCT), and maintenance lenalidomide","prefix":"ood, Ferrero et al1 present a co","suffix":". Thiswork provides further insi"}]}]}
>```
>%%
>*%%PREFIX%%ood, Ferrero et al1 present a co%%HIGHLIGHT%% ==mprehensive, longitudinalanalysis of molecular measurable residual disease (MRD) assessments inpatients with mantle cell lymphoma (MCL) treated with chemoimmunotherapy,autologous stem cell transplant (ASCT), and maintenance lenalidomide== %%POSTFIX%%. Thiswork provides further insi*
>%%LINK%%[[#^d7wfq6ke63|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^d7wfq6ke63



>%%
>```annotation-json
>{"created":"2022-09-23T13:00:12.377Z","updated":"2022-09-23T13:00:12.377Z","document":{"title":"bloodBLD2022017278C.pdf","link":[{"href":"urn:x-pdf:a9844b104ac7e761f01900b1d6ff1440"},{"href":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf"}],"documentFingerprint":"a9844b104ac7e761f01900b1d6ff1440"},"uri":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","selector":[{"type":"TextPositionSelector","start":1091,"end":1350},{"type":"TextQuoteSelector","exact":"baselinepatient and disease factors (eg, age,organ function, MIPI[Mantle Cell Lym-phoma International Prognostic Index],TP53 mutation status) have traditionallybeen studied to account for the variabil-ity in outcome associated with a giventherapeutic pathway.","prefix":"t allhematological malignancy), ","suffix":" However, acrossalmost all hemat"}]}]}
>```
>%%
>*%%PREFIX%%t allhematological malignancy),%%HIGHLIGHT%% ==baselinepatient and disease factors (eg, age,organ function, MIPI[Mantle Cell Lym-phoma International Prognostic Index],TP53 mutation status) have traditionallybeen studied to account for the variabil-ity in outcome associated with a giventherapeutic pathway.== %%POSTFIX%%However, acrossalmost all hemat*
>%%LINK%%[[#^yuvjep5ocsi|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^yuvjep5ocsi


>%%
>```annotation-json
>{"created":"2022-09-23T13:00:24.284Z","updated":"2022-09-23T13:00:24.284Z","document":{"title":"bloodBLD2022017278C.pdf","link":[{"href":"urn:x-pdf:a9844b104ac7e761f01900b1d6ff1440"},{"href":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf"}],"documentFingerprint":"a9844b104ac7e761f01900b1d6ff1440"},"uri":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","selector":[{"type":"TextPositionSelector","start":1412,"end":1499},{"type":"TextQuoteSelector","exact":"response to therapy as mea-sured by sensitive MRD methodologiesconsistently outperforms","prefix":"atological malignanciesstudied, ","suffix":" assessment ofbaseline variables"}]}]}
>```
>%%
>*%%PREFIX%%atological malignanciesstudied,%%HIGHLIGHT%% ==response to therapy as mea-sured by sensitive MRD methodologiesconsistently outperforms== %%POSTFIX%%assessment ofbaseline variables*
>%%LINK%%[[#^kllmhhbny5j|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^kllmhhbny5j


>%%
>```annotation-json
>{"created":"2022-09-23T13:02:48.543Z","updated":"2022-09-23T13:02:48.543Z","document":{"title":"bloodBLD2022017278C.pdf","link":[{"href":"urn:x-pdf:a9844b104ac7e761f01900b1d6ff1440"},{"href":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf"}],"documentFingerprint":"a9844b104ac7e761f01900b1d6ff1440"},"uri":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","selector":[{"type":"TextPositionSelector","start":2317,"end":2373},{"type":"TextQuoteSelector","exact":"negative MRD results correlated withreduced relapse risk","prefix":"ersely, the presence of multiple","suffix":".To derive these predictive time"}]}]}
>```
>%%
>*%%PREFIX%%ersely, the presence of multiple%%HIGHLIGHT%% ==negative MRD results correlated withreduced relapse risk== %%POSTFIX%%.To derive these predictive time*
>%%LINK%%[[#^si0evxk9pf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^si0evxk9pf


>%%
>```annotation-json
>{"created":"2022-09-23T13:03:10.077Z","updated":"2022-09-23T13:03:10.077Z","document":{"title":"bloodBLD2022017278C.pdf","link":[{"href":"urn:x-pdf:a9844b104ac7e761f01900b1d6ff1440"},{"href":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf"}],"documentFingerprint":"a9844b104ac7e761f01900b1d6ff1440"},"uri":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","selector":[{"type":"TextPositionSelector","start":2433,"end":2623},{"type":"TextQuoteSelector","exact":"well-established suiteof molecular MRD techniques (quantita-tive real-time polymerase chain reaction[RT-qPCR] and nested qualitative PCR)within the standardized framework of theEuroMRD group","prefix":"timepoints,Ferrero et al used a ","suffix":". This approach involvesthe desi"}]}]}
>```
>%%
>*%%PREFIX%%timepoints,Ferrero et al used a%%HIGHLIGHT%% ==well-established suiteof molecular MRD techniques (quantita-tive real-time polymerase chain reaction[RT-qPCR] and nested qualitative PCR)within the standardized framework of theEuroMRD group== %%POSTFIX%%. This approach involvesthe desi*
>%%LINK%%[[#^13s3tmg8pyub|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^13s3tmg8pyub


>%%
>```annotation-json
>{"created":"2022-09-23T13:06:26.761Z","updated":"2022-09-23T13:06:26.761Z","document":{"title":"bloodBLD2022017278C.pdf","link":[{"href":"urn:x-pdf:a9844b104ac7e761f01900b1d6ff1440"},{"href":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf"}],"documentFingerprint":"a9844b104ac7e761f01900b1d6ff1440"},"uri":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","selector":[{"type":"TextPositionSelector","start":7030,"end":7676},{"type":"TextQuoteSelector","exact":"assessment of molecularMRD is improving our ability to predictoutcome in patients with MCL. However,robust data to support changes in treat-ment approaches will only be possible ifresearchers continue to prospectivelytest MRD-guided decision strategies as apart of trial design as well as prioritizingsamples for these critical associatedcorrelative studies. With the potential forfurther novel, widely applicable and sen-sitive molecular MRD technologies in thefuture as well as ongoing trials evaluatingwell-tolerated and effective agents suchas Bruton tyrosine kinase inhibitors,MRD-guided therapy in MCL has thepotential to allow deescalation","prefix":"of Ferrero et aland others that ","suffix":"/intensification of therapy to d"}]}]}
>```
>%%
>*%%PREFIX%%of Ferrero et aland others that%%HIGHLIGHT%% ==assessment of molecularMRD is improving our ability to predictoutcome in patients with MCL. However,robust data to support changes in treat-ment approaches will only be possible ifresearchers continue to prospectivelytest MRD-guided decision strategies as apart of trial design as well as prioritizingsamples for these critical associatedcorrelative studies. With the potential forfurther novel, widely applicable and sen-sitive molecular MRD technologies in thefuture as well as ongoing trials evaluatingwell-tolerated and effective agents suchas Bruton tyrosine kinase inhibitors,MRD-guided therapy in MCL has thepotential to allow deescalation== %%POSTFIX%%/intensification of therapy to d*
>%%LINK%%[[#^sjcj3yb9udk|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^sjcj3yb9udk


>%%
>```annotation-json
>{"created":"2022-09-23T13:06:37.017Z","updated":"2022-09-23T13:06:37.017Z","document":{"title":"bloodBLD2022017278C.pdf","link":[{"href":"urn:x-pdf:a9844b104ac7e761f01900b1d6ff1440"},{"href":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf"}],"documentFingerprint":"a9844b104ac7e761f01900b1d6ff1440"},"uri":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220923/bloodbld2022017278c.pdf","selector":[{"type":"TextPositionSelector","start":7677,"end":7742},{"type":"TextQuoteSelector","exact":"intensification of therapy to deliver betteroutcomes for patients","prefix":"potential to allow deescalation/","suffix":".Conflict-of-interest disclosure"}]}]}
>```
>%%
>*%%PREFIX%%potential to allow deescalation/%%HIGHLIGHT%% ==intensification of therapy to deliver betteroutcomes for patients== %%POSTFIX%%.Conflict-of-interest disclosure*
>%%LINK%%[[#^mr8qe87zilc|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mr8qe87zilc
